Cargando…

Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia

INTRODUCTION: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamilian, Hamidreza, Solhi, Hasan, Jamilian, Mehri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Center of Science and Education 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796520/
https://www.ncbi.nlm.nih.gov/pubmed/25363186
http://dx.doi.org/10.5539/gjhs.v6n7p103
_version_ 1782421794234302464
author Jamilian, Hamidreza
Solhi, Hasan
Jamilian, Mehri
author_facet Jamilian, Hamidreza
Solhi, Hasan
Jamilian, Mehri
author_sort Jamilian, Hamidreza
collection PubMed
description INTRODUCTION: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investigated the efficacy of omega-3 fatty acid as add-on treatment in schizophrenia. MATERIAL & METHODS: A randomized, double blind, placebo controlled fixed-dose, add-on clinical trial conducted over 8 weeks. 60 patients with documented schizophrenia randomly divided into two groups: omega-3(1000 mg/day) (n=30) and placebo (n=30). Patients received omega-3 or placebo in addition to their standard antipsychotic treatment. Patient follow up was done using Positive and Negative syndrome Scale (PANSS). Data analyzed using SPSS software v.20. RESULT: At the end of 8 weeks treatment, PANSS score decreased significantly in both groups (p<0.05) in comparison to baseline. Efficacy of omega-3 in decreasing general psychopathologic and total scores was significant in comparison to placebo group from 4 and 6 weeks after onset of treatment, respectively (p<0.05). Totally, omega-3 supplement therapy efficacy in comparison to sole conventional antipsychotics was 0.86 which was not significant (p>0.05). CONCLUSION: We found that supplemental omega-3 might increase efficacy of conventional antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions and availability of omega-3 made this substance a potential supplement in improved treatment of schizophrenia.
format Online
Article
Text
id pubmed-4796520
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Canadian Center of Science and Education
record_format MEDLINE/PubMed
spelling pubmed-47965202016-04-21 Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia Jamilian, Hamidreza Solhi, Hasan Jamilian, Mehri Glob J Health Sci Articles INTRODUCTION: Recent studies found omega-3 fatty acid deficiency in brain cell membranes of schizophrenic patients. Conventional antipsychotics have many adverse reactions. Safety, availability and low price made omega-3 as a potential supplement for treatment of these patients. This study investigated the efficacy of omega-3 fatty acid as add-on treatment in schizophrenia. MATERIAL & METHODS: A randomized, double blind, placebo controlled fixed-dose, add-on clinical trial conducted over 8 weeks. 60 patients with documented schizophrenia randomly divided into two groups: omega-3(1000 mg/day) (n=30) and placebo (n=30). Patients received omega-3 or placebo in addition to their standard antipsychotic treatment. Patient follow up was done using Positive and Negative syndrome Scale (PANSS). Data analyzed using SPSS software v.20. RESULT: At the end of 8 weeks treatment, PANSS score decreased significantly in both groups (p<0.05) in comparison to baseline. Efficacy of omega-3 in decreasing general psychopathologic and total scores was significant in comparison to placebo group from 4 and 6 weeks after onset of treatment, respectively (p<0.05). Totally, omega-3 supplement therapy efficacy in comparison to sole conventional antipsychotics was 0.86 which was not significant (p>0.05). CONCLUSION: We found that supplemental omega-3 might increase efficacy of conventional antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions and availability of omega-3 made this substance a potential supplement in improved treatment of schizophrenia. Canadian Center of Science and Education 2014-12 2014-09-18 /pmc/articles/PMC4796520/ /pubmed/25363186 http://dx.doi.org/10.5539/gjhs.v6n7p103 Text en Copyright: © Canadian Center of Science and Education http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Articles
Jamilian, Hamidreza
Solhi, Hasan
Jamilian, Mehri
Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
title Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
title_full Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
title_fullStr Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
title_full_unstemmed Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
title_short Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia
title_sort randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796520/
https://www.ncbi.nlm.nih.gov/pubmed/25363186
http://dx.doi.org/10.5539/gjhs.v6n7p103
work_keys_str_mv AT jamilianhamidreza randomizedplacebocontrolledclinicaltrialofomega3assupplementaltreatmentinschizophrenia
AT solhihasan randomizedplacebocontrolledclinicaltrialofomega3assupplementaltreatmentinschizophrenia
AT jamilianmehri randomizedplacebocontrolledclinicaltrialofomega3assupplementaltreatmentinschizophrenia